Download this insight brief to learn why digitalization is a safety imperative for the pharmaceutical and biotechnical industries and what these industries can gain from digitalization beyond safety.
What’s Inside
A recent study by Wolters Kluwer Enablon in partnership with the National Safety Council (NSC) shows about 45% of surveyed organizations have achieved “mostly” or “fully” digitalized EHS processes, a number that climbs to 52% for pharmaceutical companies. Digitalizing EHS processes for pharmaceutical companies supports a movement away from fragmented, manual systems and has significant implications for workforce safety, product quality, business continuity, and patient protection.
This insight brief explains why digitalization is a safety imperative for the pharmaceutical and biotechnical industries and what these industries can gain from digitalization beyond improved safety performance. Download the insight brief to find out more.
Key Takeaways
Learn about:
- Why digital maturity matters for AI readiness
- How digitalization strengthens and streamlines reporting
- How people-centric processes benefit from digitalized systems
- The opportunities of digitalization beyond operational efficiency